MaXTC 5-MAPB/4-FMA/5-MeO-MiPT Blister

€ 55,95

MaXTC 5-MAPB/4-FMA/5-MeO-MiPT Blister is described as a multi-component laboratory research material associated with three distinct chemical classes: a benzofuran derivative, a fluorinated amphetamine derivative, and a substituted tryptamine.

Raw Lab Chems identifies this formulation exclusively for controlled chemical identification, chromatographic characterization, mass-spectrometric investigation, and comparative analytical documentation.

The supplied information claims component purity, independent testing, batch traceability, and blend uniformity. However, no batch-specific analytical records or verified component quantities were provided to substantiate these specifications.

For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

SKU: CERT-S-12567 Category:
Description

MaXTC 5-MAPB/4-FMA/5-MeO-MiPT Blister – Research Material

Product Overview

MaXTC 5-MAPB/4-FMA/5-MeO-MiPT Blister is described in the supplied information as a multi-component laboratory research preparation associated with three synthetic compounds from different chemical families.

The named components are 5-MAPB, 4-FMA, and 5-MeO-MiPT.

These substances are identified respectively as a benzofuran derivative, a fluorinated amphetamine derivative, and a substituted tryptamine.

The supplied source presents the formulation within a Research Use Only framework, with emphasis on chemical identification, analytical characterization, and comparisons involving multiple chemical classes.

The blister presentation introduces additional considerations beyond those associated with an individual unformulated compound.

These include the identity of each component, the relative composition of the preparation, the properties of any additional formulation materials, and the uniformity of the finished units.

The source describes the preparation as high purity and laboratory grade.

However, these descriptions do not independently establish the chemical composition, component ratios, actual purity, or batch consistency of the supplied material.

No clinical, therapeutic, diagnostic, dietary, or consumer-oriented application is represented by this description.    MaXTC 5-MAPB/4-FMA/5-MeO-MiPT Blister

Chemical Identity & Classification

The supplied source identifies three named compounds within the MaXTC formulation.

5-MAPB is described as 5-(2-methylaminopropyl)benzofuran, a substituted benzofuran derivative.

4-FMA is described as 4-fluoromethamphetamine, a fluorinated amphetamine derivative.

5-MeO-MiPT is described as 5-methoxy-N-methyl-N-isopropyltryptamine, a substituted tryptamine derivative.

The supplied chemical-reference information is:

Component Chemical classification Source-provided CAS number
5-MAPB Substituted benzofuran derivative 1354635-90-8
4-FMA Fluorinated amphetamine derivative 440-65-3
5-MeO-MiPT Substituted tryptamine derivative 96096-55-8

These identifiers are reproduced from the supplied information and have not been independently verified against authoritative chemical records.  MaXTC 5-MAPB/4-FMA/5-MeO-MiPT Blister

The source does not identify the precise salt or freebase form of each component.

This distinction is important because different chemical forms may have different molecular formulas, molecular weights, and analytical reference characteristics.

The supplied information also does not provide a complete quantitative composition for the mixture.

The phrase labeled amounts appears in the source, but no actual component amounts or ratios are stated.

Consequently, no quantitative blend specification can be independently established from the information provided.

Researchers seeking public chemical-reference information may consult PubChem and confirm that each selected database entry corresponds to the intended compound and chemical form.

Chemical & Physical Characteristics

The supplied product is described as a blister-packed, multi-component preparation.

No verified photographs, unit specifications, substrate information, excipient list, or physical inspection records accompanied the source.

The actual appearance and composition of the finished preparation therefore remain unconfirmed.

Because the formulation is described as containing three chemically distinct substances, the characteristics of the complete preparation cannot be inferred from the properties of any single named component.

Differences in molecular structure may influence chromatographic behavior, spectroscopic characteristics, and interactions with the surrounding analytical matrix.

However, structural classification alone does not establish specific solubility values, thermal stability, degradation behavior, or analytical recovery.

The source refers to matrix effects, stability profiles, and differential chromatographic behavior as research topics.  MaXTC 5-MAPB/4-FMA/5-MeO-MiPT Blister

No experimentally verified solubility dataset, melting-point information, physical-state characterization, or product-specific stability report was provided.

The source recommends cool, dry storage protected from light and identifies refrigeration at 2–8°C as a preferred condition.

No validated stability study was supplied to establish that this temperature range is necessary or sufficient for a particular shelf life.

Purity & Analytical Verification

The supplied information claims purity of at least 98% for each component, reportedly verified through third-party analysis.

No batch-specific Certificate of Analysis, chromatogram, mass spectrum, NMR report, or independent laboratory certificate accompanied the description.

The stated purity threshold therefore remains an unverified supplier claim.

An important distinction exists between the purity of individual chemical ingredients and the composition of the finished multi-component preparation.

Even if individual ingredient purity were established, that information would not independently confirm the relative amounts of the components or their distribution throughout the finished product.

The source references LC-MS/MS, GC-MS, LC-QTOF, and NMR spectroscopy as analytical techniques associated with the investigation of the named chemical classes.

Such techniques may provide information about identity, structural characteristics, impurity profiles, and analytical specificity.

However, naming these techniques does not establish that validated testing was performed on the actual material.

The source also references chromatographic selectivity, matrix effects, and multi-analyte detection as analytical research topics.

These references do not establish certified reference-material status, quantitative accuracy, or validated method performance.

Any purity or identity claim should be supported by records associated with the actual batch.

Quality Control & Batch Integrity

The supplied source claims that the MaXTC preparation undergoes third-party testing and batch-specific quality assurance.

It also describes Certificates of Analysis covering all three components, blend-ratio verification, homogeneity testing, and stability assessment.

No actual certificate, independent laboratory report, batch record, or supporting analytical dataset was provided.

These claims therefore remain unverified.

The source additionally refers to controlled manufacturing conditions intended to support consistent preparation quality.

No manufacturing audit, quality-system certification, or process-validation record accompanied this statement.

For institutional documentation, relevant information may include the supplier, product designation, batch number, receipt date, verified chemical identities, and any available analytical findings.

The absence of stated component quantities is a material limitation for interpreting the composition of the preparation.

Researchers should distinguish ordinary catalog material from a certified reference material with independently established composition and traceability.

No certified reference-material status, assigned measurement uncertainty, or verified quantitative composition is asserted.  MaXTC 5-MAPB/4-FMA/5-MeO-MiPT Blister

Safety, Handling & Laboratory Precautions

The named formulation combines compounds from three different synthetic chemical classes and requires appropriate institutional risk assessment.

Research personnel should consult applicable chemical-safety documentation, institutional procedures, and relevant legal requirements before receiving or examining the material.

Laboratory controls should address restricted access, protective equipment, contamination prevention, accidental exposure, environmental release, secure inventory, and chemical-waste disposal.

The presence of multiple named compounds does not establish the safety of the combined preparation.

Likewise, a blister presentation does not establish pharmaceutical suitability or authorization for human or veterinary exposure.

Because the component quantities, chemical forms, and actual blend composition have not been independently verified, laboratory records should preserve those uncertainties.

The material should remain secured against unauthorized access and separated from food, beverages, and non-research environments.

Any accidental exposure or contamination incident should be managed according to institutional emergency procedures.

Packaging, Labeling & Storage

The supplied source describes blister packaging, thermal protection, appropriate chemical labeling, and professional transportation arrangements.

No packaging-validation report, container specification, or shipment-condition record accompanied these claims.

The source recommends storage in a cool, dry environment protected from light and suggests refrigeration at 2–8°C.

No validated stability report was provided to establish a product-specific shelf life or confirm the suitability of that temperature range.

The source also claims that shipping documentation and protective packaging support regulatory compliance.

No carrier records, destination-specific authorizations, or transport-compliance documents were supplied.

Laboratory inventory records should identify the preparation as a multi-component material and preserve the names of all three reported constituents.

Any missing component ratios, unverified chemical forms, and uncertain formulation details should remain explicitly documented.

Packaging and environmental requirements should be assessed using available safety information, relevant stability evidence, and institutional laboratory procedures.

Intended Research Use & Market Positioning

The supplied scientific context places MaXTC within analytical research involving multiple synthetic chemical classes, chemical identification, structural comparison, and forensic characterization.

The named components represent benzofuran, fluorinated amphetamine, and substituted tryptamine structures.    MaXTC 5-MAPB/4-FMA/5-MeO-MiPT Blister

Their inclusion in a single catalog preparation creates a multi-component chemical identity that must be distinguished from the identity of each individual substance.

The source references chromatographic comparison, mass-spectrometric characterization, and analytical documentation as areas of laboratory investigation.

These references describe institutional research contexts and do not establish any human-use application.

For comparative catalog research, Raw Lab Chems also lists Blue Bliss Pellets and Pink Star Pellets.

Those catalog names reference 2-FMA rather than 4-FMA and therefore should not be treated as compositionally identical to the MaXTC preparation.

The supplied MaXTC product reference identifies the specific catalog presentation discussed here.

These links provide chemical-catalog context rather than evidence of analytical equivalence, certified reference-material status, or interchangeable composition.

Ordering, Availability & Fulfillment

The supplied source describes international shipping, tracking, protective packaging, and transportation arrangements intended for research institutions.

No current inventory confirmation, destination-specific authorization, carrier documentation, or verified shipment record was supplied.

Consequently, no specific availability, delivery, customs-clearance, transportation-compliance, or temperature-control guarantee is asserted.

The named compounds may be subject to controlled-substance, analog, or other chemical restrictions.

The legal classification of a multi-component preparation may depend on the status of its individual constituents and the applicable jurisdiction.

Institutional acquisition, possession, transportation, importation, and exportation must comply with all relevant legal requirements.

Research-only labeling does not create an exemption from controlled-substance legislation.

Legal & Regulatory Disclaimer

For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

MaXTC is described as a multi-component preparation associated with 5-MAPB, 4-FMA, and 5-MeO-MiPT.

One or more of these substances may be subject to jurisdiction-specific controlled-substance scheduling, analog provisions, or other chemical regulations.

The legal status of the complete preparation must be determined under the laws applicable to the relevant institution and jurisdiction.

Authorized researchers remain responsible for obtaining any necessary permissions and maintaining appropriate laboratory controls.

No medical approval, consumer-use authorization, universal legal status, or regulatory exemption is implied by this description.

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “MaXTC 5-MAPB/4-FMA/5-MeO-MiPT Blister”
Shipping & Delivery